Key clinical point: Survival benefit with nivolumab vs. docetaxel for NSCLC persists long-term.
Major finding: 5-year overall survival was 13.4% vs. 2.6% with nivolumab vs. docetaxel.
Study details: A pooled analysis of data for 870 patients from the phase 3 CheckMate 017 and 057 trials.
Disclosures: CheckMate 017 and 057 were funded by Bristol-Myers Squibb. Dr. Gettinger reported advisory board and/or consulting work for, and/or research funding from Bristol-Myers Squibb, Nektar Therapeutics, Genentech/Roche, Iovance, and Takeda/Ariad.
Gettinger S et al. WCLC 2019, Abstract PR04.03.